RNTX (Rein Therapeutics) Cash-to-Debt : No Debt ⁽¹⁾ (As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Rein Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Rein Therapeutics's cash to debt ratio for the quarter that ended in Dec. 2024 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Rein Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Dec. 2024.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Rein Therapeutics's Cash-to-Debt or its related term are showing as below:

RNTX' s Cash-to-Debt Range Over the Past 10 Years
Min: 3.63 Med: 502.19 Max: No Debt
Current: No Debt

During the past 10 years, Rein Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 3.63. And the median was 502.19.

RNTX's Cash-to-Debt is ranked better than
99.87% of 1482 companies
in the Biotechnology industry
Industry Median: 7.525 vs RNTX: No Debt

Rein Therapeutics Cash-to-Debt Historical Data

The historical data trend for Rein Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Rein Therapeutics Cash-to-Debt Chart

Rein Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash-to-Debt

Get a 7-Day Free Trial

35.67

283.54

643.70

360.69

No Debt

Rein Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Cash-to-Debt	Get a 7-Day Free Trial															360.69	No Debt	No Debt	No Debt	No Debt

Competitive Comparison of Rein Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, Rein Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rein Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rein Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Rein Therapeutics's Cash-to-Debt falls into.

Save Embed

;

Save Embed

;

Rein Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Rein Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2024 is calculated as:

Rein Therapeutics had no debt ⁽¹⁾.

Rein Therapeutics's Cash to Debt Ratio for the quarter that ended in Dec. 2024 is calculated as:

Rein Therapeutics had no debt ⁽¹⁾.

Rein Therapeutics (NAS:RNTX) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Rein Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Rein Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Rein Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rein Therapeutics Inc (NAS:RNTX) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

12407 North Mopac Expressway, Suite 250, No.390, Austin, TX, USA, 78758

Website

https://www.reintx.com

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

Executives

James Brian Windsor	officer: See Remarks	2600 VIA FORTUNA, SUITE 360, AUSTIN TX 78746
William Fairey	director	C/O CHEMOCENTRYX, INC., 850 MAUDE AVE., MOUNTAIN VIEW CA 94043
Alan A Musso	director	FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Susan L. Drexler	officer: See Remarks	630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
Muneer A Satter	10 percent owner	C/O SATTER INVESTMENT MANAGEMENT, LLC, 676 NORTH MICHIGAN AVENUE, SUITE 4000, CHICAGO IL 60611
Reinhard J. Ambros	director	C/O AILERON THERAPEUTICS, INC., 281 ALBANY STREET, CAMBRIDGE MA 02139
Von Rickenbach Josef H	director	C/O PAREXEL INTERNATIONAL CORPORATION, WALTHAM MA 02451-1163
Jeffrey Allen Bailey	director	BIODELIVERY SCIENCES INTERNATIONAL, INC., 4131 PARKLAKE AVE., SUITE 225, RALEIGH NC 27612
Vojo Vukovic	officer: SVP, Chief Medical Officer	C/O SYNTA PHARMACEUTICALS CORP., 45 HARTWELL AVENUE, LEXINGTON MA 02421
Kathryn Gregory	officer: SVP, Chief Business Officer	305 THAYER POND ROAD, WILTON CT 06897
William Mckee	director
Nolan Howard Sigal	director	941 BERRY AVENUE, LOS ALTOS CA 94024
Novartis Bioventures Ltd	10 percent owner	C/O NOVARTIS INTERNATIONAL AG, WSJ-200.220, CH-4002 BASEL V8 0000000000
Rick Wanstall	officer: VP, Finance and Operations	C/O AILERON THERAPEUTICS, INC., 490 ARSENAL WAY, WATERTOWN MA 02472
Longenecker John P Phd	officer: President and CEO	10445 PACIFIC CENTER CT, SAN DIEGO CA 92121